Critical Analysis: Nutriband (NASDAQ:NTRB) versus Sanara MedTech (NASDAQ:SMTI)

Sanara MedTech (NASDAQ:SMTI) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Sanara MedTech and Nutriband”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$72.41 million	3.50	-$4.30 million	($0.59)	-49.78
Nutriband	$1.80 million	36.71	-$5.49 million	($0.77)	-7.79

Sanara MedTech has higher revenue and earnings than Nutriband. Sanara MedTech is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sanara MedTech and Nutriband, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	0	0	1	0	3.00
Nutriband	0	0	0	0	N/A

Sanara MedTech presently has a consensus price target of $44.00, suggesting a potential upside of 49.81%. Given Sanara MedTech’s higher probable upside, research analysts plainly believe Sanara MedTech is more favorable than Nutriband.

Profitability

This table compares Sanara MedTech and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-9.07%	-15.17%	-8.94%
Nutriband	-401.39%	-66.60%	-56.41%

Insider & Institutional Ownership

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 54.1% of Sanara MedTech shares are held by company insiders. Comparatively, 43.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Sanara MedTech has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Summary

Sanara MedTech beats Nutriband on 10 of the 13 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.